{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:08:08Z","timestamp":1791976088617,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Ministerie van Volksgezondheid, Welzijn en Sport","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.euo.2026.05.014","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:39:26Z","timestamp":1783539566000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6530-5925","authenticated-orcid":false,"given":"Joyce","family":"Greidanus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margriet C.","family":"van Dijk - de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Calareso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Bruining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"Westerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailin","family":"Dehghanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Tissier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"van Dorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal F.","family":"Stockem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christodoulos","family":"Pipinikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk G.","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina G.H.","family":"Beets-Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Giannatempo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Trebeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry N.","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.05.014_b0005","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.05.014_b0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41585-021-00505-w","article-title":"Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop","volume":"19","author":"Chang","year":"2022","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2026.05.014_b0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.05.014_b0020","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.euo.2026.05.014_b0025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data","volume":"48","author":"Vale","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.05.014_b0030","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S1470-2045(17)30602-2","article-title":"New option for cisplatin-ineligible urothelial cancer","volume":"18","author":"Dreicer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.05.014_b0035","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm","volume":"36","author":"Necchi","year":"2018","journal-title":"Phase II study. J Clin Oncol"},{"key":"10.1016\/j.euo.2026.05.014_b0040","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2026.05.014_b0045","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.05.014_b0050","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/amj.2020.02.01","article-title":"Bladder preservation therapy in muscle-invasive bladder cancer: current evidence and future perspectives","volume":"5","author":"Tanaka","year":"2020","journal-title":"AME Med J"},{"key":"10.1016\/j.euo.2026.05.014_b0055","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.euo.2023.02.008","article-title":"A systematic review of oncological outcomes associated with bladder-sparing strategies in patients achieving complete clinical response to initial systemic treatment for localized muscle-invasive bladder cancer","volume":"6","author":"Grobet-Jeandin","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.05.014_b0060","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/cancers15030566","article-title":"Current and future landscape of perioperative treatment for muscle-invasive bladder cancer","volume":"15","author":"Esteban-Villarrubia","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2026.05.014_b0065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/jmri.27361","article-title":"VI-RADS for bladder cancer: current applications and future developments","volume":"55","author":"Panebianco","year":"2022","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.euo.2026.05.014_b0070","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.eururo.2019.12.016","article-title":"Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: preliminary findings from the PURE-01 study","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.05.014_b0075","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00261-021-03365-5","article-title":"Vesical Imaging-Reporting and Data System (VI-RADS) for assessment of response to systemic therapy for bladder cancer: preliminary report","volume":"47","author":"Pecoraro","year":"2022","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.euo.2026.05.014_b0080","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/his.13734","article-title":"Staging of bladder cancer","volume":"74","author":"Magers","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.euo.2026.05.014_b0085","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2026.05.014_b0090","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.3390\/cancers15225468","article-title":"Multiparametric MRI in era of artificial intelligence for bladder cancer therapies","volume":"15","author":"Akin","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2026.05.014_b0095","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2214\/AJR.14.13732","article-title":"Treatment response assessment for bladder cancer on CT based on computerized volume analysis, World Health Organization criteria, and RECIST","volume":"205","author":"Hadjiiski","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.euo.2026.05.014_b0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fnhum.2019.00213","article-title":"Analysis of perceptual expertise in radiology - current knowledge and a new perspective","volume":"13","author":"Waite","year":"2019","journal-title":"Front Hum Neurosci"},{"key":"10.1016\/j.euo.2026.05.014_b0105","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41591-022-02199-y","article-title":"High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial","volume":"29","author":"van Dorp","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2026.05.014_b0110","unstructured":"ClinicalTrials.gov. Study details. https:\/\/clinicaltrials.gov\/study\/NCT04871594."},{"key":"10.1016\/j.euo.2026.05.014_b0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-46450-1","article-title":"Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors","volume":"15","author":"Gil-Jimenez","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.05.014_b0120","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12880-024-01441-y","article-title":"Retrospective analysis of multiparametric MRI in predicting complete pathologic response of neo-adjuvant chemotherapy in bladder cancer","volume":"24","author":"De Maeseneer","year":"2024","journal-title":"BMC Med Imaging"},{"key":"10.1016\/j.euo.2026.05.014_b0125","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233020","article-title":"Neoadjuvant chemotherapy VI-RADS scores for assessing muscle-invasive bladder cancer response to neoadjuvant immunotherapy with multiparametric MRI","volume":"313","author":"Brembilla","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.euo.2026.05.014_b0130","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.euo.2025.03.005","article-title":"Challenges in defining clinical complete response to systemic therapy in muscle-invasive bladder cancer: insights from the EORTC STARBURST project","volume":"8","author":"Masson-Lecomte","year":"2025","journal-title":"European Urology Oncology"},{"key":"10.1016\/j.euo.2026.05.014_b0135","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1007\/s00330-024-11327-w","article-title":"Diagnostic accuracy and inter-reader agreement of the nacVI-RADS for bladder cancer treated with neoadjuvant chemotherapy: a prospective validation study","volume":"35","author":"Dehghanpour","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.euo.2026.05.014_b0140","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.222176","article-title":"Automation bias in mammography: the impact of artificial intelligence BI-RADS suggestions on reader performance","volume":"307","author":"Dratsch","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.euo.2026.05.014_b0145","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","article-title":"Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting and Data System)","volume":"74","author":"Panebianco","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.05.014_b0150","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/iju.14974","article-title":"Relationship between the number of lymph nodes dissected and prognosis in muscle-invasive bladder cancer in the era of neoadjuvant chemotherapy","volume":"29","author":"Tochigi","year":"2022","journal-title":"Int J Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:31:06Z","timestamp":1785882666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"alternative-id":["S2588931126001549"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.05.014","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}